What is Noble Financial’s Forecast for ELDN Q1 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities researchers at Noble Financial issued their Q1 2026 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research report issued to clients and investors on Monday, March 23rd. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of ($0.08) for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.91) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.10.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.67.

Eledon Pharmaceuticals Stock Performance

Shares of ELDN opened at $2.89 on Wednesday. The firm has a market cap of $219.21 million, a PE ratio of -5.56 and a beta of 0.84. The firm’s 50 day moving average price is $2.39 and its 200 day moving average price is $2.35. Eledon Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.60.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in Eledon Pharmaceuticals by 143.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company’s stock worth $31,000 after purchasing an additional 7,166 shares during the last quarter. ProShare Advisors LLC bought a new stake in Eledon Pharmaceuticals during the second quarter worth approximately $33,000. Millennium Management LLC acquired a new position in Eledon Pharmaceuticals during the fourth quarter valued at approximately $36,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Eledon Pharmaceuticals during the second quarter valued at approximately $37,000. Finally, Virtu Financial LLC bought a new position in shares of Eledon Pharmaceuticals in the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 56.77% of the company’s stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.